Three announcements in the last week helped...
Three announcements in the last week helped propel Rohr Industries 1 7/8 to 34 3/4, according to Irving Katz, director of research for San Diego Securities.
During an interview with Dow Jones, Rohr forecast a 21% increase in annual sales to $800 million. Rohr expects earnings to rise by 34% to 44%.
The company also announced that it would purchase Fairchild’s composite bonding center in Hagerstown, Md., for an undisclosed amount. Last week the company filed for $100 million in convertible debentures.
Molecular Biosystems made a new high of 15 1/2 and closed the week up 2 1/8 to 14 1/8 on the announcement that the Food & Drug Administration would treat its Albunex ultrasound contrast imaging agent as a medical device. That classification could ultimately lead to more rapid market approval, Katz said.
Fabulous Inns was up one-half to 4 1/2 as the latest controlling management group offered to purchase all public shares for $6 each.
Good gains were also shown by WD-40, up 1 to 35; Synbiotics, up one to 8 3/4, and, Mycogen, plus three-quarters to 10 1/2. Xscribe, which went public at 8 and dropped to 6 1/2, recovered somewhat to close up three-quarters at 7 1/2.
Cubic Corp. was up seven-eighths to 21 3/4 after telling its story on the Financial News Network.
On the downside, Xytronyx dropped three-quarters to 12 after announcing new financing as it privately placed $500,000 in 8 1/2% convertible notes, convertible at $10 per share.
Video Library was down three-eighths to 3 3/8 in response to adverse articles on the intense competition in the video store industry.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.